Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. (CLRB) on May 17, 2026. The report discloses changes to the Board of Directors, including the departure of a director and the appointment of a new director following a recent securities purchase agreement.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and a specific compensatory arrangement.
Material Changes
- Director Departure: Stefan D. Loren, Ph.D., notified the Board on May 17, 2026, that he will not stand for reelection as a Class III director at the 2026 Annual Meeting. His departure is not due to any disagreement with the Company.
- Consulting Agreement: The Company entered into a consulting agreement with Dr. Loren effective July 8, 2026. Terms include $15,000 per quarter for one year and a stock option grant of 15,000 shares at the end of the term.
- New Director Appointment: Pursuant to a Board Designation Side Letter with Nantahala Capital Management, LLC (Nantahala) from a May 4, 2026 securities purchase agreement, Andrew Gu was appointed to the Board as a Class III director on May 18, 2026. He also joined the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The only disclosed contingency is the appointment of the Nantahala designee, which was subject to Board approval (not unreasonably withheld) and was completed on May 18, 2026.
Key Facts for Investor Verification
- Verify the terms of the May 4, 2026 securities purchase agreement with institutional investors that triggered the Board seat appointment.
- Confirm the impact of Dr. Loren's departure on the Company's scientific strategy, given his role as a director.
- Review the full text of the consulting agreement with Dr. Loren to understand the scope of services and vesting terms for the 15,000 share option grant.
- Assess the qualifications and potential conflicts of interest of the new director, Andrew Gu, who is an analyst at the investing hedge fund Nantahala.